The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus – outcomes from cross‐over open-label randomized trial

BACKGROUND AND AIMS: Diabetes mellitus type two is one of the major cardiovascular risk factors. Treatment of diabetes can reduce this risk, but the treatment options differ a lot in their risk-reducing capabilities. We compared the impact of insulin degludec (IDeg-100) and insulin glargine U300 (IG...

Descripción completa

Detalles Bibliográficos
Autores principales: Cindro, Pavle Vrebalov, Krnić, Mladen, Modun, Darko, Smajić, Božo, Vuković, Jonatan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082786/
https://www.ncbi.nlm.nih.gov/pubmed/33926446
http://dx.doi.org/10.1186/s12902-021-00746-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082786/
https://www.ncbi.nlm.nih.gov/pubmed/33926446
http://dx.doi.org/10.1186/s12902-021-00746-1

Ejemplares similares